JP2024522106A5 - - Google Patents
Info
- Publication number
- JP2024522106A5 JP2024522106A5 JP2023573112A JP2023573112A JP2024522106A5 JP 2024522106 A5 JP2024522106 A5 JP 2024522106A5 JP 2023573112 A JP2023573112 A JP 2023573112A JP 2023573112 A JP2023573112 A JP 2023573112A JP 2024522106 A5 JP2024522106 A5 JP 2024522106A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide
- dsrna agent
- modified nucleotide
- nucleotides
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194073P | 2021-05-27 | 2021-05-27 | |
| US63/194,073 | 2021-05-27 | ||
| US202163289319P | 2021-12-14 | 2021-12-14 | |
| US63/289,319 | 2021-12-14 | ||
| PCT/US2022/031337 WO2022251629A2 (en) | 2021-05-27 | 2022-05-27 | Compositions and methods for silencing carbonic anhydrase 2 expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522106A JP2024522106A (ja) | 2024-06-11 |
| JP2024522106A5 true JP2024522106A5 (https=) | 2025-06-04 |
Family
ID=84230316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023573112A Pending JP2024522106A (ja) | 2021-05-27 | 2022-05-27 | 炭酸脱水酵素２発現をサイレンシングするための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240254493A1 (https=) |
| EP (1) | EP4347836A4 (https=) |
| JP (1) | JP2024522106A (https=) |
| KR (1) | KR20240014109A (https=) |
| AU (1) | AU2022280088A1 (https=) |
| BR (1) | BR112023024269A2 (https=) |
| CA (1) | CA3220604A1 (https=) |
| IL (1) | IL308574A (https=) |
| MX (1) | MX2023014008A (https=) |
| WO (1) | WO2022251629A2 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| HUE033977T2 (en) * | 2004-08-23 | 2018-02-28 | Sylentis Sau | Treatment of eye disorders with siRNAs characterized by increased intraocular pressure |
| TW200639252A (en) * | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
| RU2487716C2 (ru) * | 2007-10-03 | 2013-07-20 | Кварк Фармасьютикалс, Инк. | Новые структуры малых интерферирующих рнк (sirna) |
| ES2351005B1 (es) * | 2009-07-10 | 2011-11-18 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de anhidrasa carbónica ii para la elaboración de un medicamento. |
| WO2017019660A1 (en) * | 2015-07-27 | 2017-02-02 | Alnylam Pharmaceuticals, Inc. | Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof |
| MX2020011570A (es) * | 2018-05-07 | 2020-11-24 | Alnylam Pharmaceuticals Inc | Administracion extrahepatica. |
| WO2022026531A1 (en) * | 2020-07-29 | 2022-02-03 | Alnylam Pharmaceuticals, Inc. | Atxn2 irna compositions and methods of use thereof for treating or preventing atxn2-associated neurodegenerative diseases |
-
2022
- 2022-05-27 KR KR1020237045007A patent/KR20240014109A/ko active Pending
- 2022-05-27 CA CA3220604A patent/CA3220604A1/en active Pending
- 2022-05-27 IL IL308574A patent/IL308574A/en unknown
- 2022-05-27 AU AU2022280088A patent/AU2022280088A1/en active Pending
- 2022-05-27 BR BR112023024269A patent/BR112023024269A2/pt unknown
- 2022-05-27 MX MX2023014008A patent/MX2023014008A/es unknown
- 2022-05-27 WO PCT/US2022/031337 patent/WO2022251629A2/en not_active Ceased
- 2022-05-27 EP EP22812254.5A patent/EP4347836A4/en active Pending
- 2022-05-27 US US18/562,787 patent/US20240254493A1/en not_active Abandoned
- 2022-05-27 JP JP2023573112A patent/JP2024522106A/ja active Pending
-
2024
- 2024-08-30 US US18/820,997 patent/US20250084418A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5592892B2 (ja) | 眼障害の治療方法 | |
| CA2210998C (en) | Inhibition of neovascularization using vegf-specific oligonucleotides | |
| EP1141278B1 (en) | Therapeutic pde4d phosphodiesterase inhibitors | |
| US5661135A (en) | Human VEGF-specific oligonucleotides | |
| JP2022501057A5 (https=) | ||
| US6897201B2 (en) | Compositions and methods for the treatment of glaucoma or ocular hypertension | |
| IL297129A (en) | Carriers for efficient nucleic acid delivery | |
| JP2023506181A5 (https=) | ||
| RU2008130855A (ru) | ОПОСРЕДОВАННОЕ РНКI ИНГИБИРОВАНИЕ Rho-КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ НАРУШЕНИЙ | |
| US20190144865A1 (en) | Modified tgf-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease | |
| US20050130931A1 (en) | Compositions for the treatment of glaucoma or ocular hypertension | |
| JP2013537404A (ja) | Ｒｈｏａに対する二本鎖ｒｎａ化合物およびその使用 | |
| JP2024522106A5 (https=) | ||
| JP2024538646A5 (https=) | ||
| JP2024526234A5 (https=) | ||
| US20050282769A1 (en) | Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage | |
| US20140323549A1 (en) | Methods and compositions for treating diseases, disorders or injury of the nervous system | |
| MX2008014750A (es) | Oligonucleotidos que afectan la expresion de fosfodiesterasas. | |
| RU2653766C2 (ru) | КиРНК И ИХ ИСПОЛЬЗОВАНИЕ В СПОСОБАХ И КОМПОЗИЦИЯХ ДЛЯ ЛЕЧЕНИЯ И/ИЛИ ПРОФИЛАКТИКИ ГЛАЗНЫХ ЗАБОЛЕВАНИЙ | |
| US20170058279A1 (en) | siRNAs and Their Use in Methods and Compositions for the Treatment and/or Prevention of Eye Conditions | |
| JP2023514190A5 (https=) | ||
| IL295445A (en) | Preparations and methods for silencing vegf-a expression | |
| Adams et al. | Recent developments for the treatment of glaucoma | |
| WO2025213136A1 (en) | Oligonucleotides comprising pn linkages and methods thereof | |
| CA2214431C (en) | Human vegf-specific antisense oligonucleotides |